ACAM 529

Drug Profile

ACAM 529

Alternative Names: ACAM529; dl5-29 HSV-2 vaccine - Acambis; Herpes vaccine - Harvard Medical School/Acambis; HSV-529

Latest Information Update: 25 Oct 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Harvard Medical School
  • Developer National Institute of Allergy and Infectious Diseases; Sanofi Pasteur
  • Class Antivirals; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Herpes simplex virus infections

Most Recent Events

  • 04 Oct 2017 Safety and Immunogenicity data from a phase I trial in Herpes Simplex virus infection presented at the ID Week 2017
  • 23 Mar 2017 ACAM 529 is still in phase I trials for Herpes simplex virus infections in USA (NCT01915212)
  • 06 Mar 2017 NIAID and Sanofi Pasteur complete a phase I trial in Herpes simplex virus infections in USA (NCT01915212)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top